ESC 2013: Medtronic's Symplicity hypertension treatment still promising at 1 and 3 years

Tue, 09/03/2013 - 2:27pm
Mass Device

A pair of Medtronic studies support the Symplicity renal denervation system in treatment of patients with drug-resistant hypertension, with promising results at 1 and 3 years following treatment.

ESC 2013: Medtronic renal denervation going strong at 3 years

New data on Medtronic's (NYSE:MDT) Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week.

A pair of analyses released during the the European Society of Cardiology Congress in Amsterdam this week showed positive results for the hypertension treatment system.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.